Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
- Ana Oaknin(corresponding author),
- ,
- Yuka Kasamatsu,
- Marta Gil-Martin,
- Juan Francisco Grau-Bejar,
- Carmen Garcia-Duran
- Vall d'Hebron Institute of Oncology,
- ,
- Shizuoka Cancer Center,
- Institute Catala Oncologia,
- Merck KGaA,
- Saitama Medical University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Purpose: Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFb receptor II (a TGFb “trap”) fused to a human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer. Patients and Methods: In this multicenter, open-label, phase Ib trial (NCT04551950), patients with P/R/M cervical cancer received bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with (Cohort 1A; n ¼ 8) or without (Cohort 1B; n ¼ 9) bevacizumab; patients with locally advanced cervical cancer received bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2; n ¼ 8). The primary endpoint was safety; secondary endpoints included efficacy (including objective response rate) and pharmacokinetics. Results: At the data cutoff of April 27, 2022, patients in Cohorts 1A, 1B, and 2 had received bintrafusp alfa for a median duration of 37.9, 31.1, and 16.7 weeks, respectively. Two dose-limiting toxicities (grade 4 amylase elevation and grade 3 menorrhagia) unrelated to bintrafusp alfa were observed in Cohort 1B and none in other cohorts. Most treatment-emergent adverse events of special interest were grades 1–2 in severity, most commonly anemia (62.5%–77.8%) and bleeding events (62.5%–77.8%). Objective response rate was 75.0% [95% confidence interval (CI), 34.9–96.8], 44.4% (95% CI, 13.7–78.8), and 62.5% (95% CI, 24.5–91.5) in Cohorts 1A, 1B, and 2, respectively. Conclusions: Bintrafusp alfa had manageable safety and demonstrated clinical activity, further supporting the investigation of TGFb/PD-L1 inhibition in human papillomavirus–associated cancers, including cervical cancer.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 975-983 (9 pages)Journal (Volume, Issue Number)
Clinical Cancer Research (Volume 30, Issue 5)Publication milestones
- Published - 03/01/2024
Publication status
Published - 03/01/2024
ISSN
1078-0432Publication IDs
- Scopus: 85186745319
- PubMed: 38165683
Publication metrics
Metrics
Fractional count
1
Fractional count
0.09
Fractional count
10
Fractional count
0.91
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
13
Citation count
15
Mentions
2
Funding Details
The authors thank the patients and their families, investigators, coinvestigators, and study teams at each of the participating centers and at the healthcare business of Merck KGaA, Darmstadt, Germany. Medical writing support was provided by Rebecca Yao, PhD, and Joyce Lee, PhD, of MediTech Media Asia Pacific, which was funded by the healthcare business of Merck KGaA (CrossRef Funder ID: 10.13039/100009945) and was previously part of an alliance between the healthcare business of Merck KGaA and GlaxoSmithKline, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).
FundersFunding number
MediTech Media Asia Pacific
-Rebecca Yao
-healthcare business of Merck KGaA
-Merck KGaA
-GSK
GPP 2022
